title: [Oral administration of OK-432 (Picibanil) (7th report). Clinical application: effects on advanced and recurrent cancers].
authors.forename: Y
authors.initials: Y
authors.lastname: Nio
authors.forename: K
authors.initials: K
authors.lastname: Ohgaki
authors.forename: N
authors.initials: N
authors.lastname: Kan
authors.forename: T
authors.initials: T
authors.lastname: Tsuchitani
authors.forename: S
authors.initials: S
authors.lastname: Imai
authors.forename: T
authors.initials: T
authors.lastname: Okino
authors.forename: T
authors.initials: T
authors.lastname: Hori
authors.forename: T
authors.initials: T
authors.lastname: Tobe
authors.forename: M
authors.initials: M
authors.lastname: Nakamura
authors.forename: H
authors.initials: H
authors.lastname: Kodama
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D001688:Biological Products / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007116:Immunization, Passive; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000188:drug therapy*; D010844:Picibanil / Q000008:administration & dosage* / Q000627:therapeutic use; D010865:Pilot Projects
chemical_list: D001688:Biological Products; D010844:Picibanil